JUNSHealthcare · Biotechnology

JUNS Stock Forecast: Jupiter Neurosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$6.20

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$4.8M

Ticker Nerd rank

11 / 100

Median analyst target

—

Analysts covering

Revenue$19K

Operating income−$2.0M

Net income−$2.1M

Free cash flow−$1.4M

Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown

Ticker Nerd rank

JUNS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jupiter Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Momentum

Revisions

Growth

Value

Quality

Issuance

Size (97): Smaller than most of the companies we track.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JUNS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JUNS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JUNS appears on the weeks it earns a place.

Estimates

JUNS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Jupiter Neurosciences, Inc. (JUNS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.3×
Price / sales: 73.8×
Price / book: −1.1×
EV / EBITDA: −0.6×

Growth & margins

Revenue growth (YoY): −14.4%
Earnings growth (YoY): —
Gross margin: 76.6%
Operating margin: −11313.4%
Net margin: 80.6%

Returns & dividend

Return on equity: −1888.7%
Return on assets: −159.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Jupiter Neurosciences, Inc. (JUNS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Jupiter Neurosciences, Inc. has a market value of $4.8M and an enterprise value of $5.0M.
Revenue in the twelve months to 31 Mar 2026: $40K. The latest quarter shrank 14.4% year on year.
Net income over the same four quarters: −$9.2M, a −22690.8% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$5.8M.
Shares outstanding: 483,750.
Trailing P/E: −0.3×; forward P/E: 103.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Jupiter Neurosciences, Inc. employs 5 people — $8K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 23 Aug 2026

Data provided by Twelve Data

Peers

JUNS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
JUNSJupiter Neurosciences, Inc.	$4.8M	11
GOVXGeoVax Labs, Inc.	$4.8M	29
VIVSVivoSim Labs, Inc.	$4.7M	30
APVOAptevo Therapeutics, Inc.	$4.8M	26
MLECMoolec Science SA	$5.1M	3
GLMDGalmed Pharmaceuticals Ltd.	$4.5M	19
JAGXJaguar Health, Inc.	$4.5M	57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jupiter Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JUNS news & analysis

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

GlobeNewsWire · 21 Aug 2026neutral

Jupiter Neurosciences announced it has entered into a securities purchase agreement for a registered direct offering, pricing $2.0 million through the sale of 307,692 shares of common stock. The offering was priced on August 21, 2026.

Why it matters — JUNS watchers would care because the company is raising additional capital through a registered direct offering, which affects its share count and funding position.

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

Benzinga · 21 Aug 2026positive

Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) were surging Friday morning after related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.

Why it matters — This is relevant to JUNS watchers because the surge is tied to corporate news from its biotechnology partner PharmAla, including a newly granted U.S. patent.

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

GlobeNewsWire · 5 Aug 2026neutral

Jupiter Neurosciences, Inc. announced a reverse stock split, with its common stock expected to begin trading on a post-split adjusted basis on August 7, 2026.

Why it matters — A reverse stock split reduces the number of outstanding shares and typically increases the per-share price, which can affect how the stock is perceived by exchanges and investors.

FAQ

Frequently asked questions about JUNS stock

Is JUNS stock a buy right now?

Of the 1 analysts covering Jupiter Neurosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jupiter Neurosciences, Inc. 11 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JUNS?

As at 22 Aug 2026, Jupiter Neurosciences, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the JUNS stock forecast for 2030?

No analyst covering Jupiter Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JUNS are extrapolating price history, which says nothing about the business.

What does Jupiter Neurosciences, Inc. do?

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and related central nervous system disorders.

What is the latest news on JUNS?

The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering". Jupiter Neurosciences announced it has entered into a securities purchase agreement for a registered direct offering, pricing $2.0 million through the sale of 307,692 shares of common stock. The offering was priced on August 21, 2026.

Company

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and related central nervous system disorders. Based in Jupiter, Florida and founded in 2015, the company is built around a proprietary resveratrol-based drug platform designed to deliver this compound in a more effective and bioavailable oral form. Its lead product candidate, JOTROL, targets a broad range of conditions where neuroinflammation is a key component, including various neurodegenerative and rare diseases. Jupiter Neurosciences also integrates its platform into consumer-oriented longevity and wellness formulations under the Nugevia brand, addressing areas such as mitochondrial support, cognitive health, and skin vitality. Operating within the healthcare and biotechnology sectors, the company primarily serves unmet medical needs in CNS and rare disease markets, positioning its resveratrol platform at the intersection of clinical therapeutics and scientifically grounded wellness solutions.

CEO Mr. Christer Rosen · 5 employees · United States · https://jupiterneurosciences.com